37 Essential Drugs Including Paracetamol, Atorvastatin To Get Cheaper, NPPA Issues Revised Price List
New Delhi: Through a recent Gazette notification, the National Pharmaceutical Pricing Authority (NPPA), under the Ministry of Chemicals and Fertilizers, has fixed the retail prices of 37 widely used essential drug formulations, including those used to treat infections, heart diseases, inflammatory conditions, diabetes, and vitamin deficiencies.
Notable among the revised formulations is a triple-combination anti-inflammatory tablet containing Aceclofenac, Paracetamol, and Trypsin Chymotrypsin. The NPPA has capped its retail price at Rs 13 per tablet when marketed by Dr. Reddy’s Laboratories and Rs 15.01 when marketed by Cadila Pharmaceuticals. Another major change affects the cardiovascular segment: a bilayer tablet combining Atorvastatin 40 mg and Clopidogrel 75 mg is now priced at Rs 25.61 per unit.
The revised list also includes several pediatric oral suspensions—such as those based on Cefixime and Paracetamol—as well as key nutritional and injectable therapies. For instance, Cholecalciferol (Vitamin D) drops and Diclofenac injection have been priced at Rs 6.11 per ml and Rs 31.77 per ml, respectively.
In the anti-diabetic segment, critical combinations such as Empagliflozin, Sitagliptin, and Metformin Hydrochloride—used extensively in type 2 diabetes management—are now capped at Rs 16.50 per tablet. Fixed-dose cholesterol medications like Atorvastatin-Ezetimibe and respiratory therapies including Bilastine-Montelukast for allergic rhinitis and asthma also feature among the newly priced formulations.
In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the Authority has fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Table
Sl. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1 | Aceclofenac, Paracetamol & Trypsin Chymotrypsin Tablets | Each enteric coated tablet contains: Proteolytic enzymes Trypsin & Chymotrypsin in the ratio of Approximately 6:1 and provides enzymatic activity Eq. to 1,50,000 Armour units Aceclofenac IP 100 mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Dr. Reddy’s Laboratories Ltd. | 13.00 |
Sl. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
Paracetamol IP 325 mg | |||||
2 | Aceclofenac, Paracetamol & Trypsin Chymotrypsin Tablets | Each enteric coated tablet contains: Proteolytic enzymes Trypsin & Chymotrypsin in the ratio of Approximately 6:1 and provides enzymatic activity Eq. to 1,50,000 Armour units Aceclofenac IP 100 mg Paracetamol IP 325 mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Cadila Pharmaceuticals Ltd. | 15.01 |
3 | Amoxycillin & Potassium Clavulanate Oral suspension | Each 5 ml of reconstituted suspension contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin 600 mg Potassium Clavulanate Diluted IP equivalent to Clavulanic Acid 42.9 mg | 1 ml | M/s Copmed Pharmaceuticals Pvt. Ltd./ M/s Zydus Healthcare Ltd. | 3.32 |
4 | Atorvastatin & Clopidogrel Tablets | Each uncoated bilayered tablet contains: Atorvastatin Calcium IP Equivalent to Atorvastatin 40 mg Clopidogrel Bisulphate IP equivalent to Clopidogrel 75 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Lupin Ltd. | 25.61 |
5 | Atorvastatin & Ezetimibe Tablets | Each Film Coated Tablet Contains: Atorvastatin Calcium IP Eq. to Atorvastatin 10 mg Ezetimibe IP 10 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Cadila Pharmaceuticals Ltd. | 19.86 |
6 | Atorvastatin & Ezetimibe Tablets | Each Film Coated Tablet Contains: Atorvastatin Calcium IP Eq. to Atorvastatin 20 mg Ezetimibe IP 10 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Cadila Pharmaceuticals Ltd. | 30.10 |
7 | Atorvastatin & Ezetimibe Tablets | Each Film Coated Tablet Contains: Atorvastatin Calcium IP Eq. to Atorvastatin 40 mg Ezetimibe IP 10 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Cadila Pharmaceuticals Ltd. | 30.47 |
8 | Atorvastatin Calcium and Clopidogrel Capsules | Each hard gelatin capsule contains: Atorvastatin Calcium IP equivalent to Atorvastatin 10mg (As pellets) Clopidogrel Bisulphate IP equivalent to Clopidogrel 75mg (As pellets) | 1 Capsule | M/s Synokem Pharmaceuticals Ltd./ M/s Alkem Laboratories Ltd. | 15.94 |
9 | Atorvastatin, Clopidogrel and Aspirin Capsules | Each hard gelatin capsule contains: Atorvastatin Calcium IP Eqv. to Atorvastatin 10 mg (As Pellets) Clopidogrel Bisulphate İP Eq. to Clopidogrel 75 mg (As Pellets) Aspirin IP 75 mg (As enteric coated Pellets) | 1 Capsule | M/s Synokem Pharmaceuticals Ltd./ M/s Aristo Laboratories Pvt. Ltd. | 5.88 |
10 | Atorvastatin, Clopidogrel and Aspirin Capsules | Each hard gelatin capsule contains: Atorvastatin Calcium IP Eqv. to Atorvastatin 20 mg (As Pellets) Clopidogrel Bisulphate IP | 1 Capsule | M/s Synokem Pharmaceuticals Ltd./ M/s Aristo Laboratories Pvt. Ltd. | 8.33 |
Sl. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
Eq. to Clopidogrel 75 mg (As Pellets) Aspirin IP 75 mg (As enteric coated Pellets) | |||||
11 | Bilastine & Montelukast Tablet | Each film coated bilayered tablet contains: Bilastine IP 40 mg Montelukast Sodium IP eq. to Montelukast 10 mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Lupin Ltd. | 22.78 |
12 | Bisoprolol Fumarate & Amlodipine Tablets | Each film coated tablet contains: Bisoprolol Fumarate IP 2.5 mg Amlodipine Besylate IP equivalent to Amlodipine 5 mg | 1 Tablet | M/s Swiss Garnier Life Sciences/ M/s Cadila Pharmaceuticals Ltd. | 6.70 |
13 | Cefixime Oral Suspension (Combipack) | One Combipack contains: Part (A) Each 5ml of reconstituted suspension contains: Cefixime IP equivalent to Cefixime Anhydrous 200 mg Part (B) Each ampoule contains Sterile Water for Injection IP 25ml | 1 ml | M/s Alps Communication Pvt. Ltd./ M/s Aristo Pharmaceuticals Pvt. Ltd. | 3.72 |
14 | Cefixime, Dicloxacillin (CR) and Lactic Acid Bacillus Tablets | Each film coated tablet contains: Cefixime IP as Trihydrate Eq. to Anhydrous Cefixime 200mg Dicloxacillin Sodium IP Eq. to Dicloxacillin 500 mg (Controlled release) Lactic Acid Bacillus 2.5 Billion Spores (Appropriate Overages of Lactic Acid Bacillus Spores Added) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Alkem Laboratories Ltd. | 15.25 |
15 | Cholecalciferol Oral Drops | Each ml contains: Cholecalciferol (Vitamin D3) IP 800 IU (as Stabilized) | 1 ml | M/s Ravenbhel Biotech/ M/s Zydus Healthcare Ltd. | 6.11 |
16 | Cilnidipine & Telmisartan Tablets | Each film coated tablet contains: Cilnidipine IP 20 mg Telmisartan IP 40 mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Lupin Ltd. | 14.51 |
17 | Diclofenac Sodium, Paracetamol & Chlorzoxazone Tablets | Each uncoated tablet contains: Diclofenac Sodium IP 50 mg Paracetamol IP 325 mg Chlorzoxazone USP 250 mg | 1 Tablet | M/s Innova Captab Ltd./ M/s Dr. Reddys Laboratories Ltd. | 6.03 |
18 | Escitalopram Oxalate & Clonazepam Tablets | Each Film Coated Tablet Contains: Escitalopram Oxalate IP eq.to Escitalopram 5 mg Clonazepam IP 0.25 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Abbott Healthcare Pvt. Ltd. | 8.38 |
19 | Paracetamol, Phenylephrine Hydrochloride & Chlorpheniramine Maleate Tablets | Each uncoated tablet contains: Paracetamol IP 500 mg Phenylephrine Hydrochloride IP 10 mg Chlorpheniramine Maleate IP 2 mg | 1 Tablet | M/s East African (I) Overseas / M/s Troikaa Pharmaceuticals Ltd. | 5.15 |
20 | Empagliflozin, Linagliptin & | Each film coated bilayer tablet contains: | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Corona Remedies Pvt. | 33.13 |
Sl. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
Metformin Hydrochloride (Extended Release) Tablets | Empagliflozin 25 mg Linagliptin 5 mg Metformin Hydrochloride IP 1000 mg (as extended release) | Ltd. | |||
21 | Empagliflozin, Sitagliptin & Metformin Hydrochloride (Extended Release) Tablets | Each film coated bilayer tablet contains: Empagliflozin 25 mg Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 100 mg Metformin Hydrochloride IP 1000 mg (as extended release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s USV Ltd. | 27.50 |
22 | Empagliflozin, Sitagliptin & Metformin Hydrochloride (Extended Release) Tablets | Each film coated bilayer tablet contains: Empagliflozin 25 mg Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 100 mg Metformin Hydrochloride IP 1000 mg (as extended release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Micro Labs Ltd. | 16.50 |
23 | Empagliflozin, Sitagliptin & Metformin Hydrochloride (Extended Release) Tablets | Each film coated bilayer tablet contains: Empagliflozin 25 mg Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 100 mg Metformin Hydrochloride IP 1000 mg (as extended release) | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Aristo Pharmaceuticals Pvt. Ltd. | 17.42 |
24 | Empagliflozin, Sitagliptin & Metformin Hydrochloride (Extended Release) Tablets | Each film coated bilayer tablet contains: Empagliflozin 10 mg Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 100 mg Metformin Hydrochloride IP 1000 mg (as extended release) | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Aristo Pharmaceuticals Pvt. Ltd. | 14.74 |
25 | Empagliflozin & Metformin Hydrochloride Tablets | Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Eris Lifesciences Ltd. | 18.70 |
26 | Empagliflozin & Metformin Hydrochloride Tablets | Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Windlas Biotech Ltd./ M/s Medley Pharmaceuticals Ltd. | 13.40 |
27 | Empagliflozin & Metformin Hydrochloride Tablets | Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 1000 mg | 1 Tablet | M/s Windlas Biotech Ltd./ M/s Medley Pharmaceuticals Ltd. | 14.30 |
28 | Sitagliptin + Pioglitazone + Metformin Hydrochloride (Sustained Release) Tablets | Each film coated bilayered tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Workcell Solutions Pvt. Ltd. | 14.11 |
Sl. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
to Pioglitazone 15mg Metformin Hydrochloride IP (as sustained release form) 500mg | |||||
29 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated bilayered tablet contains: Sitagliptin Phosphate Monohydrate IP 64.25 mg equivalent to Sitagliptin 50 mg Glimepiride IP 1 mg Metformin Hydrochloride IP 1000 mg | 1 Tablet | M/s Tristar Formulations Pvt. Ltd/ M/s Franco Indian Pharmaceuticals Pvt. Ltd. | 11.16 |
30 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated bilayered tablet contains: Sitagliptin Phosphate Monohydrate IP 64.25 mg equivalent to Sitagliptin 50 mg Glimepiride IP 2 mg Metformin Hydrochloride IP 1000 mg | 1 Tablet | M/s Tristar Formulations Pvt. Ltd/ M/s Franco Indian Pharmaceuticals Pvt. Ltd. | 12.59 |
31 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50mg Glimepiride IP 1 mg Metformin Hydrochloride IP 500mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Primus Remedies Pvt. Ltd. | 12.19 |
32 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50mg Glimepiride IP 1 mg Metformin Hydrochloride IP 500mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Aristo Pharmaceuticals Pvt. Ltd. | 11.52 |
33 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50mg Glimepiride IP 2 mg Metformin Hydrochloride IP 500mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Primus Remedies Pvt. Ltd. | 13.87 |
34 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50mg Glimepiride IP 2 mg Metformin Hydrochloride IP 500mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Aristo Pharmaceuticals Pvt. Ltd. | 14.69 |
35 | Paracetamol, Phenylephrine HCl, Chlorpheniramine Maleate suspension | Each 5 ml contains: Paracetamol IP 250 mg Phenylephrine Hydrochloride IP 5 mg Chlorpheniramine Maleate IP 2 mg | 1 ml | M/s Res-Sancta Limited / M/s Biological E. Limited | 0.71 |
36 | Paracetamol, Phenylephrine HCl, | Each 5ml (teaspoonful) contains: Paracetamol IP 250 mg | 1 ml | M/s Windlas Biotech Limited / M/s Biological E. Limited | 0.41 |
Sl. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
Chlorpheniramine Maleate, Ammonium Chloride, Sodium Citrate & Menthol suspension | Phenylephrine Hydrochloride IP 5 mg Chlorpheniramine Maleate IP 2 mg Ammonium Chloride IP 120 mg Sodium Citrate IP 60 mg Menthol IP 1 mg | ||||
37 | Diclofenac Injection | Each ml contains: Diclofenac Sodium IP 75 mg | 1ml | M/s Nitin Lifesciences Ltd. /M/s. Mankind Prime Labs Pvt. Ltd. | 31.77 |
The notification further mentioned;
- The manufacturer of above-mentioned formulations i.e., ―new drug‖ under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
- In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.